Orexigen Therapeutics and rebmeM join the Alliance
This month, we’re excited to welcome Orexigen Therapeutics and rebmeM as the newest members of the Alliance.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba® (naltrexone HCl/ bupropion HCl prolonged release). Orexigen is undertaking a range of commercialization activities, both on their own and with key strategic partners, to bring Contrave / Mysimba to patients around the world. Learn more about Orexigen Therapeutics.
rebmeM is a consulting & solution implementation partner focused on transforming the health insurance member experience into a value add consumer experience. We believe to be successful, benefit providers must adopt new technologies & processes, shedding the limiting processes & technologies used in the past. We utilize CRM, applied predictive analytics & other solution capabilities to help organizations transform the member experience into a true consumer experience and provide value beyond what is typically provided today. Learn more about rebmeM.
Published: September 9, 2016